Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to compare efficacy and safety of infliximab biosimilar (IB) and infliximab bio-original (IO) in rheumatoid arthritis

Trial Profile

A clinical study to compare efficacy and safety of infliximab biosimilar (IB) and infliximab bio-original (IO) in rheumatoid arthritis

Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Jul 2018

At a glance

  • Drugs Infliximab (Primary)
  • Indications Rheumatoid arthritis; Spondylarthritis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2018 New trial record
    • 07 Jun 2018 Results assessing survival and safety of infliximab bio-original and infliximab biosimilar (CT-P13) were published in the Clinical and Experimental Rheumatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top